Facing the Future Together

Mark your calendars for May 5th, 2018, for a day of SCD education for patients, families and providers!  This one day sickle cell disease conference will provide information about current trends in treatment and available resources for patients, family members, caregivers and providers. The morning session is targeted to healthcare providers and offers 3 CME credits for physicians. The afternoon session is for patients, family members and social service providers is not eligible for CME credit.

The event is free for patients and their families.  There is a small registration fee for Health Care professionals.

Click here to view the agenda.

Click here to view the MSCDA Facing the Future Together conference flyer.

Share this post

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."